Newsroom

Extra! Extra!
Read all about it

Welcome to our Newsroom, your go-to source for the latest updates on Galapagos. Explore press releases, insightful blogs, and access our resource hub, complete with company materials, designed to provide media and journalists with comprehensive information about our company’s innovations and milestones

Press releasesDownload Center

The latest

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Galapagos today announced additional data from the ongoing Phase 1/2 ATALANTA-1 study of its CD19 CAR T-cell therapy, GLPG5101. The results, featured in an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, demonstrate an encouraging efficacy and safety profile in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL).

Read more

The latest

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

Galapagos today announced that it will present new data from its CAR T- and TCR T-cell therapy pipeline at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, 7-10 December 2024.

Read more

The latest

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

Galapagos announced financial results for the first nine months of 2024 and provided a business update.

Read more

STORIES

Press releases

View All Press Releases

Follow our journey

Subscribe to receive our press releases

Do you want to stay up to date on our journey, as we are pioneering for patients?

Subscribe to our press releasesContact Media Relations